CGT Manufacturing Capacity: Battle of the CDMOs
Capacity has been built for cell and gene therapy manufacturing, but will demand keep pace? CDMOs may face a battle for survival.
| 2 min read | Hot Topic
Advanced Therapies week took place at the start of 2025. What were the key conversations? One of the key issues right now is the potential for an economic downturn and how it could affect the sector. Many CDMOs, for example, have been building capacity excepting a boom in the cell and gene business, but may now face a race for survival.
Despite the potential for a downturn, exciting progress is still happening. We can expect to see more therapies reaching patients, but this means optimizing trials and delivery networks. Check out this selection of videos on these topics.
Battle of the CDMOs
Contract manufacturers are leading the sharp rise in CGT manufacturing capacity. However, the need for CGT manufacturing has not kept up with the enormous race to build capacity and with a potential economic downturn on the horizon, the CGT CDMO business will need to fight to survive. SK pharmteco's John Lee, Resilience’s Evan Pasenello, and RosalinCT’s Catherine Tomaro-Duchesneau discuss what experience, expertise, and business models CGT companies should consider when evaluating a potential CDMO partner and debate the future of the market.
Considering Clinical Readiness
What are the pieces required for an effective CGT clinical experience? There are urgent barriers to delivery at the clinical stage. In this panel discussion, ScaleReady’s Josh Ludwig, Germfree’s Carol Houts, Title21’s Heather Purvis and allogeneic CGT expert Priya Baraniak share insights into the technology, knowledge-sharing, training, standardization, and regulatory environment needed to successfully treat more patients.
How Can the Blood Industry Work as a Network for CGT?
In the drive for patient access to CGTs, representatives from the Blood & Cell Advocacy Roster (BCAR) explain the potential of a "network of networks” knitting together stakeholder groups involved in CGT starting materials – including patient advocates, blood component suppliers, enabling technology companies and more.
